Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 4/20 | 0.60 |
| ▸ | UBA3 | Q8TBC4 | 4/20 | 0.60 |
| ▸ | ATG7 | O95352 | 10/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782900 | 0.87 | NAE1 (0.46) | NAE1UBA3ATG7 | |
| SCHEMBL783024 | 0.76 | NAE1 (0.49) | NAE1UBA3ATG7 | |
| SCHEMBL16261748 | 0.76 | HTT (0.36) | NAE1UBA3ATG7HTTSMN1; SMN2 | |
| SCHEMBL16261749 | 0.76 | HTT (0.35) | NAE1UBA3ATG7HTTSMN1; SMN2 | |
| SCHEMBL12452072 | 0.72 | NAE1 (0.79) | NAE1UBA3ATG7CDK1CCNB1 | |
| SCHEMBL805394 | 0.71 | NAE1 (0.83) | NAE1UBA3CDK1CCNB1CCNA2 | |
| SCHEMBL10283824 | 0.70 | NAE1 (0.77) | NAE1UBA3CDK1CCNB1CCNA2 | |
| SCHEMBL782316 | 0.67 | NAE1 (0.80) | NAE1UBA3 | |
| SCHEMBL782746 | 0.63 | ATG7 (0.31) | ATG7 | |
| SCHEMBL783539 | 0.62 | NAE1 (0.50) | NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071482-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071482-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | NAE1 24/4885UBA3 6/4885ATG7 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.